Michael G. King
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Michael G. King
Earlier roles on record: CFO at SAB Biotherapeutics, Inc. (SABS) until June 4, 2024. SAB Biotherapeutics, Inc. reported in an 8-K filed May 31, 2024 that Michael G. King resigned as Chief Financial Officer, effective June 4, 2024.
“On May 26, 2024, Michael King, Jr., Chief Financial Officer of the Company, informed the Company that he will resign from his position with the Company, effective June 4, 2024, to pursue another opportunity.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2024-06-04
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.